Eli Lilly (LLY)

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a turbulent four-year period of consolidation and the "Great Rationalization," a surge of institutional capital and the industrialization of Artificial Intelligence (AI) have ignited

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders.

Viking should have plenty of news to share with investors this year.

Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.

Data on Stocktwits showed retail sentiment is leaning ‘bearish’ on SPY and QQQ.

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio.

And there's more than one way to monetize this technology.

It's an easy way to quickly own 150-plus companies growing at a solid clip.

Eli Lilly isn't a one-trick pony.

Eli Lilly continues to pursue smart acquisitions for the long term.

Growth, value, or both?

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding 130,000 jobs—nearly double the consensus forecast of 65,000—the "blowout" report signals that the American economy

In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026. While the broader indices grappled with a "valuation reset" triggered by shifts in Federal Reserve leadership and a cooling

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price growth and defense. While the technology sector continues to ride a wave of massive capital investment into artificial

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.

Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.

On February 11, 2026, Meta Platforms Inc. (NASDAQ: META) officially broke ground on a sprawling $10 billion data center campus in Lebanon, Indiana, marking a monumental shift in the company’s infrastructure strategy. The 1-gigawatt (1GW) facility, situated within the state’s burgeoning LEAP Research and Innovation District, is designed

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying technology giants, investors have executed a massive "Great Rotation," fleeing overextended tech valuations in favor of the stability and renewed